Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry

Daniel Perez-Zsolt; Itziar Erkizia; Maria Pino; Mónica García-Gallo; Maria Teresa Martin; Susana Benet; Jakub Chojnacki; María Teresa Fernández-Figueras; Dolores Guerrero; Victor Urrea; Xabier Muñiz-Trabudua; Leonor Kremer; Javier Martinez-Picado; Nuria Izquierdo-Useros

doi:10.1038/s41564-019-0453-2

Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry

Daniel Perez-Zsolt, Itziar Erkizia, Maria Pino, Mónica García-Gallo, Maria Teresa Martin, Susana Benet, Jakub Chojnacki, María Teresa Fernández-Figueras, Dolores Guerrero, Victor Urrea, Xabier Muñiz-Trabudua, Leonor Kremer, Javier Martinez-Picado, Nuria Izquierdo-Useros

Research output: Contribution to journal › Article › Research

50 Citations (Scopus)

Abstract

© 2019, The Author(s), under exclusive licence to Springer Nature Limited. Several Ebola viruses cause outbreaks of lethal haemorrhagic fever in humans, but developing therapies tackle only Zaire Ebola virus. Dendritic cells (DCs) are targets of this infection in vivo. Here, we found that Ebola virus entry into activated DCs requires the sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169), which recognizes sialylated gangliosides anchored to viral membranes. Blockage of the Siglec-1 receptor by anti-Siglec-1 monoclonal antibodies halted Ebola viral uptake and cytoplasmic entry, offering cross-protection against other ganglioside-containing viruses such as human immunodeficiency virus type 1.

Original language	English
Pages (from-to)	1558-1570
Number of pages	13
Journal	Nature Microbiology
Volume	4
Issue number	9
DOIs	https://doi.org/10.1038/s41564-019-0453-2
Publication status	Published - 3 Jun 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41564-019-0453-2

Cite this

Perez-Zsolt, D., Erkizia, I., Pino, M., García-Gallo, M., Martin, M. T., Benet, S., Chojnacki, J., Fernández-Figueras, M. T., Guerrero, D., Urrea, V., Muñiz-Trabudua, X., Kremer, L., Martinez-Picado, J., & Izquierdo-Useros, N. (2019). Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry. Nature Microbiology, 4(9), 1558-1570. https://doi.org/10.1038/s41564-019-0453-2

@article{d06268bfafe04c7899ff8a4a4986c1fb,

title = "Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry",

abstract = "{\textcopyright} 2019, The Author(s), under exclusive licence to Springer Nature Limited. Several Ebola viruses cause outbreaks of lethal haemorrhagic fever in humans, but developing therapies tackle only Zaire Ebola virus. Dendritic cells (DCs) are targets of this infection in vivo. Here, we found that Ebola virus entry into activated DCs requires the sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169), which recognizes sialylated gangliosides anchored to viral membranes. Blockage of the Siglec-1 receptor by anti-Siglec-1 monoclonal antibodies halted Ebola viral uptake and cytoplasmic entry, offering cross-protection against other ganglioside-containing viruses such as human immunodeficiency virus type 1.",

author = "Daniel Perez-Zsolt and Itziar Erkizia and Maria Pino and M{\'o}nica Garc{\'i}a-Gallo and Martin, \{Maria Teresa\} and Susana Benet and Jakub Chojnacki and Fern{\'a}ndez-Figueras, \{Mar{\'i}a Teresa\} and Dolores Guerrero and Victor Urrea and Xabier Mu{\~n}iz-Trabudua and Leonor Kremer and Javier Martinez-Picado and Nuria Izquierdo-Useros",

year = "2019",

month = jun,

day = "3",

doi = "10.1038/s41564-019-0453-2",

language = "English",

volume = "4",

pages = "1558--1570",

journal = "Nature Microbiology",

issn = "2058-5276",

publisher = "Nature Research",

number = "9",

}

Perez-Zsolt, D, Erkizia, I, Pino, M, García-Gallo, M, Martin, MT, Benet, S, Chojnacki, J, Fernández-Figueras, MT, Guerrero, D, Urrea, V, Muñiz-Trabudua, X, Kremer, L, Martinez-Picado, J & Izquierdo-Useros, N 2019, 'Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry', Nature Microbiology, vol. 4, no. 9, pp. 1558-1570. https://doi.org/10.1038/s41564-019-0453-2

TY - JOUR

T1 - Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry

AU - Perez-Zsolt, Daniel

AU - Erkizia, Itziar

AU - Pino, Maria

AU - García-Gallo, Mónica

AU - Martin, Maria Teresa

AU - Benet, Susana

AU - Chojnacki, Jakub

AU - Fernández-Figueras, María Teresa

AU - Guerrero, Dolores

AU - Urrea, Victor

AU - Muñiz-Trabudua, Xabier

AU - Kremer, Leonor

AU - Martinez-Picado, Javier

AU - Izquierdo-Useros, Nuria

PY - 2019/6/3

Y1 - 2019/6/3

N2 - © 2019, The Author(s), under exclusive licence to Springer Nature Limited. Several Ebola viruses cause outbreaks of lethal haemorrhagic fever in humans, but developing therapies tackle only Zaire Ebola virus. Dendritic cells (DCs) are targets of this infection in vivo. Here, we found that Ebola virus entry into activated DCs requires the sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169), which recognizes sialylated gangliosides anchored to viral membranes. Blockage of the Siglec-1 receptor by anti-Siglec-1 monoclonal antibodies halted Ebola viral uptake and cytoplasmic entry, offering cross-protection against other ganglioside-containing viruses such as human immunodeficiency virus type 1.

AB - © 2019, The Author(s), under exclusive licence to Springer Nature Limited. Several Ebola viruses cause outbreaks of lethal haemorrhagic fever in humans, but developing therapies tackle only Zaire Ebola virus. Dendritic cells (DCs) are targets of this infection in vivo. Here, we found that Ebola virus entry into activated DCs requires the sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169), which recognizes sialylated gangliosides anchored to viral membranes. Blockage of the Siglec-1 receptor by anti-Siglec-1 monoclonal antibodies halted Ebola viral uptake and cytoplasmic entry, offering cross-protection against other ganglioside-containing viruses such as human immunodeficiency virus type 1.

UR - http://www.mendeley.com/research/antisiglec1-antibodies-block-ebola-viral-uptake-decrease-cytoplasmic-viral-entry

UR - https://www.scopus.com/pages/publications/85067016278

U2 - 10.1038/s41564-019-0453-2

DO - 10.1038/s41564-019-0453-2

M3 - Article

C2 - 31160823

SN - 2058-5276

VL - 4

SP - 1558

EP - 1570

JO - Nature Microbiology

JF - Nature Microbiology

IS - 9

ER -

Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this